ArriVent BioPharma

Update in progress

AVBP (NasdaqGM)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on medicines for cancer patients with unmet needs. Its lead candidate, firmonertinib, is a tyrosine kinase inhibitor being tested in NSCLC with EGFR mutations, including exon 20 insertion in Phase 3 and other activating EGFRm mutations in Phase 1b. The company also develops ARR-217 (an antibody-drug conjugate for GI cancers) and ARR-002, ARR-421, ARR-173 for solid tumors, with multiple strategic partnerships. Incorporated in 2021 and based in Newtown Square, PA.